On May 13, InnoCare Pharma released its first quarter 2025 performance report, which opened with a striking cash and related account balance of 7.78 billion yuan. This figure not only lays a solid foundation for the company's current development, but also paves a broad road for its future strategic layout.

InnoCare Pharma's performance in the first quarter was also outstanding. The company's revenue increased by 129.9% year-on-year to 380 million yuan, and it successfully achieved a net profit of 14 million yuan, reversing the loss trend of the same period last year.

Such outstanding achievements are inseparable from the outstanding contribution of its core products and the efficient promotion of market expansion.

The core product Obtunib continued to perform well, with sales revenue increasing by 89.2% year-on-year to RMB 310 million, becoming the core engine of performance growth. After its three major indications, especially marginal zone lymphoma, were included in the medical insurance, the market expansion effect was significant. In addition, the company's commercialization team continued to strengthen its execution capabilities, and multiple parties worked together to promote the market penetration of obeticholic acid. In April 2025, Obtunib expanded into new territory and was approved for the first-line treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, and was selected as a Level I recommendation in the "Guidelines for the Diagnosis and Treatment of Lymphoma of the Chinese Society of Clinical Oncology (CSCO) (2025 Edition)", injecting new vitality into its subsequent growth.

In addition, driven by commercialization and external cooperation, InnoCare Pharma continues to optimize its commercialization team, improve efficiency, expand the market for products such as Obtunib, and reach a licensing agreement with Prolium to obtain a down payment, using multiple channels to help increase revenue.

While building a solid foundation for its performance, InnoCare Pharma is moving rapidly on its R&D pipeline.

The application for marketing approval of the innovative treatment option of tancitumomab has been accepted in mainland China and included in the priority review, and has been approved for marketing in Hong Kong, Macao and Taiwan and approved for use in Boao and the Greater Bay Area.

The independently developed new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review status. The new drug application (NDA) of zurletrectinib for the treatment of patients with advanced solid tumors carrying NTRK fusion genes has been accepted in China, and it is expected to become the first independently developed TRK inhibitor approved for marketing in China.

The independently developed BCL2 inhibitor mesutoclax (ICP-248) has been approved for a Phase II single-arm registration clinical trial in China for the treatment of relapsed/refractory mantle cell lymphoma, and the enrollment of patients in a Phase III registration clinical trial in combination with obeticholic acid as a first-line treatment for CLL/SLL is accelerating. At the same time, mesutoclax has been granted breakthrough therapy designation. This is the first BCL2 inhibitor in China to receive BTD designation, which will help further strengthen InnoCare Pharma's dominant position in the field of hematological tumors.

Conclusion: Looking ahead, InnoCare Pharma will continue to uphold the innovation-driven development concept, and with its abundant cash flow of RMB 7.78 billion, it will accelerate the development of multiple Phase III registered clinical trials, increase investment in differentiated ADCs and other pipelines, and bring more innovative therapies to patients around the world.

https://news.yaozh.com/archive/45459.html